CEFAZOLIN

Cefazolin Adverse Events Reported to the FDA Over Time

How are Cefazolin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cefazolin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cefazolin is flagged as the suspect drug causing the adverse event.

Most Common Cefazolin Adverse Events Reported to the FDA

What are the most common Cefazolin adverse events reported to the FDA?

Anaphylactic Reaction	108 (2.25%)
Anaphylactic Shock	88 (1.83%)
Pyrexia	79 (1.64%)
Rash	79 (1.64%)
Blood Pressure Decreased	77 (1.6%)
Erythema	70 (1.46%)
Hypotension	67 (1.39%)
Alanine Aminotransferase Increased	50 (1.04%)
Aspartate Aminotransferase Increase...	47 (.98%)
Pruritus	47 (.98%)
Urticaria	45 (.94%)
	Show More
Convulsion	44 (.92%)
Drug Rash With Eosinophilia And Sys...	43 (.9%)
Dyspnoea	42 (.87%)
Drug Hypersensitivity	41 (.85%)
Tachycardia	40 (.83%)
Depressed Level Of Consciousness	39 (.81%)
Toxic Epidermal Necrolysis	39 (.81%)
Medication Error	38 (.79%)
Drug Exposure During Pregnancy	36 (.75%)
Cardiac Arrest	35 (.73%)
Nausea	34 (.71%)
Hepatic Function Abnormal	31 (.65%)
Diarrhoea	30 (.62%)
Bronchospasm	29 (.6%)
Platelet Count Decreased	29 (.6%)
Loss Of Consciousness	28 (.58%)
Sepsis	26 (.54%)
Shock	26 (.54%)
Status Epilepticus	26 (.54%)
Generalised Erythema	25 (.52%)
Hypersensitivity	25 (.52%)
Renal Failure	23 (.48%)
Blood Creatinine Increased	22 (.46%)
Dysarthria	22 (.46%)
Pneumonia	22 (.46%)
Pancytopenia	21 (.44%)
Staphylococcal Infection	21 (.44%)
Disseminated Intravascular Coagulat...	20 (.42%)
Drug Eruption	20 (.42%)
Drug Ineffective	20 (.42%)
International Normalised Ratio Incr...	20 (.42%)
Rash Erythematous	20 (.42%)
Condition Aggravated	19 (.4%)
Headache	19 (.4%)
Malaise	19 (.4%)
Vomiting	19 (.4%)
Chills	18 (.37%)
Cough	18 (.37%)
Jaundice	18 (.37%)
Oedema	18 (.37%)
Poor Quality Drug Administered	18 (.37%)
Pseudomembranous Colitis	18 (.37%)
Thrombocytopenia	18 (.37%)
Chorioamnionitis	17 (.35%)
Hypertension	17 (.35%)
Stevens-johnson Syndrome	17 (.35%)
Caesarean Section	16 (.33%)
Hepatitis	16 (.33%)
Procedural Complication	16 (.33%)
Renal Failure Acute	16 (.33%)
Respiratory Failure	16 (.33%)
Abdominal Pain	15 (.31%)
Blood Pressure Systolic Decreased	15 (.31%)
Dyskinesia	15 (.31%)
Heart Rate Increased	15 (.31%)
Liver Disorder	15 (.31%)
Multi-organ Failure	15 (.31%)
Oxygen Saturation Decreased	15 (.31%)
Post Procedural Complication	15 (.31%)
Respiratory Arrest	15 (.31%)
Anaphylactoid Reaction	14 (.29%)
Blood Bilirubin Increased	14 (.29%)
Face Oedema	14 (.29%)
Haemolytic Anaemia	14 (.29%)
White Blood Cell Count Increased	14 (.29%)
Angioedema	13 (.27%)
Anxiety	13 (.27%)
Blister	13 (.27%)
Blood Creatine Phosphokinase Increa...	13 (.27%)
Cardio-respiratory Arrest	13 (.27%)
Cellulitis	13 (.27%)
Drug Interaction	13 (.27%)
Erythema Multiforme	13 (.27%)
Myoclonus	13 (.27%)
Wheezing	13 (.27%)
Blood Alkaline Phosphatase Increase...	12 (.25%)
Blood Lactate Dehydrogenase Increas...	12 (.25%)
Chest Pain	12 (.25%)
Dysphagia	12 (.25%)
Gamma-glutamyltransferase Increased	12 (.25%)
Haemorrhage	12 (.25%)
Respiratory Distress	12 (.25%)
Blood Urea Increased	11 (.23%)
Clostridium Difficile Colitis	11 (.23%)
Drug Level Increased	11 (.23%)
Electrocardiogram St Segment Elevat...	11 (.23%)
Heart Rate Decreased	11 (.23%)
Muscular Weakness	11 (.23%)
Ventricular Tachycardia	11 (.23%)
Arthralgia	10 (.21%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Cefazolin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cefazolin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cefazolin

What are the most common Cefazolin adverse events reported to the FDA?

Epidermal And Dermal Conditions	490 (10.2%)
Allergic Conditions	290 (6.04%)
Neurological	192 (4%)
Respiratory	174 (3.62%)
Cardiac And Vascular Investigations	160 (3.33%)
Cardiac Arrhythmias	140 (2.91%)
Infections - Pathogen Unspecified	140 (2.91%)
Hepatobiliary	138 (2.87%)
Hematology Investigations	136 (2.83%)
Bacterial Infectious	135 (2.81%)
Hepatic And Hepatobiliary	128 (2.67%)
	Show More
Decreased And Nonspecific Blood Pre...	109 (2.27%)
Renal Disorders	95 (1.98%)
Body Temperature Conditions	92 (1.92%)
Gastrointestinal Signs	89 (1.85%)
Seizures	86 (1.79%)
Medication Errors	85 (1.77%)
Procedural And Device Related Injur...	69 (1.44%)
Angiedema And Urticaria	60 (1.25%)
Bronchial Disorders	54 (1.12%)
Therapeutic And Nontherapeutic Effe...	53 (1.1%)
Renal And Urinary Tract Investigati...	50 (1.04%)
Chemical Injury And Poisoning	49 (1.02%)
Enzyme	44 (.92%)
Movement Disorders	44 (.92%)
Coronary Artery	42 (.87%)
Anemias Nonhemolytic And Marrow Dep...	39 (.81%)
Administration Site Reactions	38 (.79%)
Musculoskeletal And Connective Tiss...	37 (.77%)
Lower Respiratory Tract Disorders	36 (.75%)
White Blood Cell	35 (.73%)
Gastrointestinal Motility And Defec...	34 (.71%)
Muscle	30 (.62%)
Urinary Tract Signs	30 (.62%)
Coagulopathies And Bleeding Diathes...	28 (.58%)
Embolism And Thrombosis	26 (.54%)
Immunology And Allergy	24 (.5%)
Platelet	23 (.48%)
Upper Respiratory Tract Disorders	23 (.48%)
Injuries	22 (.46%)
Metabolic, Nutritional And Blood Ga...	22 (.46%)
Vascular	22 (.46%)
Gastrointestinal Ulceration And Per...	21 (.44%)
Hemolyses And Related Conditions	21 (.44%)
Physical Examination Topics	21 (.44%)
Placental, Amniotic And Cavity Diso...	21 (.44%)
Vascular Hypertensive	21 (.44%)
Myocardial	20 (.42%)
Anxiety Disorders	19 (.4%)
Headaches	19 (.4%)
Heart Failures	19 (.4%)
Obstetric And Gynecological Therape...	19 (.4%)
Pleural	19 (.4%)
Electrolyte And Fluid Balance Condi...	18 (.37%)
Eye	18 (.37%)
Gastrointestinal Inflammatory Condi...	18 (.37%)
Joint	18 (.37%)
Pulmonary Vascular	18 (.37%)
Bone And Joint Injuries	17 (.35%)
Hematological And Lymphoid Tissue T...	17 (.35%)
Oral Soft Tissue Conditions	17 (.35%)
Central Nervous System Vascular	16 (.33%)
Fatal Outcomes	16 (.33%)
Exocrine Pancreas Conditions	15 (.31%)
Microbiology And Serology	15 (.31%)
Ocular Neuromuscular	15 (.31%)
Protein And Chemistry Analyses	15 (.31%)
Toxicology And Therapeutic Drug Mon...	15 (.31%)
Deliria	14 (.29%)
Ocular Infections, Irritations And ...	13 (.27%)
Skin Vascular Abnormalities	13 (.27%)
Vascular Hemorrhagic	13 (.27%)
Encephalopathies	12 (.25%)
Gastrointestinal Hemorrhages	12 (.25%)
Neonatal And Perinatal Conditions	12 (.25%)
Nephropathies	12 (.25%)
Water, Electrolyte And Mineral	12 (.25%)
Cardiac Disorder Signs	11 (.23%)
Peritoneal And Retroperitoneal Cond...	11 (.23%)
Viral Infectious	11 (.23%)
Maternal Complications Of Labour An...	10 (.21%)
Skin Appendage Conditions	10 (.21%)
Mental Impairment	9 (.19%)
Pericardial	9 (.19%)
Respiratory And Pulmonary Investiga...	9 (.19%)
Acid-base	8 (.17%)
Bone, Calcium, Magnesium And Phosph...	8 (.17%)
Fungal Infectious	8 (.17%)
Psychiatric	8 (.17%)
Gallbladder	7 (.15%)
Investigations, Imaging And Histopa...	7 (.15%)
Therapeutic Procedures And Supporti...	7 (.15%)
Anterior Eye Structural Change, Dep...	6 (.12%)
Aural	6 (.12%)
Gastrointestinal Tract Disorders Co...	6 (.12%)
Increased Intracranial Pressure And...	6 (.12%)
Purine And Pyrimidine Metabolism	6 (.12%)
Spleen, Lymphatic And Reticulendoth...	6 (.12%)
Appetite And General Nutritional	5 (.1%)
Communication Disorders	5 (.1%)
Gastrointestinal Stenosis And Obstr...	5 (.1%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cefazolin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cefazolin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.